Page 8 - Pharmaceutical Companies

Natco Pharma Q1 net profit rises multi-fold to Rs 320 cr on higher revenue

Its consolidated revenue from operations during the quarter under review stood at Rs 884.6 crore compared to Rs 410.3 crore in the same period last fiscal, it added.

BioNTech reports strong H1 with $9.7-bn revenue, expects demand to grow

The German pharmaceutical company said Monday that revenue hit about 9.57 billion euros ($ 9.76 bn) in the first six months of 2022, up from nearly 7.36 billion euros in the same period a year earlier

Sun Pharmaceutical Industries Chairman Israel Makov to retire on Aug 29

Makov is retiring upon the completion of his current term post the company's Annual General Meeting after having led the Mumbai-based company for ten years

Rupee at 80: Neutral impact for India's pharma industry, say experts

India's pharma sector exported drugs worth Rs 1.8 trillion in 2021-22, while APIs worth Rs 30,000 crore were imported

Indian pharma industry may rebound to 8-11% growth rate, says Alkem

Alkem Laboratories expects the Indian pharmaceutical industry to rebound to 8-11 per cent growth rate with normalcy in activities as the pandemic eases out

Biocon Biologics' antibody drug unit in Bengaluru gets EU GMP certificate

Approval comes from Irish health regulator, which had flagged some deficiencies in the manufacturing process iin May

Specialty business set to spur growth for Sun Pharma in next 3 yrs: Experts

Global specialty drug sales for Sun Pharma have grown by 39% YoY in FY22 to $674 million

Near-term outlook prescription for diagnostic firms looks fragile

Competitive pressures, high valuations limit upsides for listed lab chains

Indoco Remedies gets final nod from US FDA for Lacosamide tablet

Pharmaceuticals firm Indoco Remedies Ltd on Tuesday said it has received final approval from the US health regulator for its generic Lacosamide tablet indicated for prevention and control of seizures. The approval granted by the US Food & Drug Administration (USFDA) for Lacosamide tablets is for strengths of 50 mg, 100 mg, 150 mg and 200 mg. These are the generic version of Vimpat Tablets of UCB Inc, the company said in a regulatory filing. Indoco Remedies Managing Director Aditi Kare Panandikar said, "The ANDA approval for Lacosamide Tablets on the day of patent expiry, reverberates our enduring commitment to make quality and affordable generic medicines available to more patients in the United States. Our first shipment of Lacosamide tablets has already reached the US". Lacosamide tablets are indicated for the prevention and control of seizures. It is an anticonvulsant/antiepileptic drug, the company said. Citing IQVIA sales data for the period ending January 2022, the company ..

Macleods Pharmaceuticals recalls products in US for manufacturing issues

Macleods Pharmaceuticals is recalling two products in the US market due to deviation from standard manufacturing norms, according to a USFDA report.

Pharma industry likely to grow to $130 billion by 2030: Industry leaders

'As India becomes an increasingly more important component for the global supply chain, that should benefit the industry going forward,' Sun Pharma Managing Director Dilip Shanghvi said

Piramal Enterprises Q3 profit rises 11% to Rs 888 crore

The company had posted a net profit of Rs 799 crore for the same period last fiscal year

Pharma company Venus Remedies joins AMR Industry Alliance

AMR Industry Alliance is the largest private-sector coalition working towards curbing AMR through a coordinated and multipronged response

Budget 2022: Pharma industry seeks enhanced funds for healthcare sector

The domestic pharmaceutical industry is expecting an increase in the overall fund allocation for the healthcare sector, focus on policies that encourage R&D activities and continuation of tax concessions on various drugs in the upcoming Union Budget. The industry is also seeking simplification of various processes in order to enhance ease of doing business for the private sector companies. "An increase in the budgetary allocation from the current 1.8 per cent of the GDP to 2.5-3 per cent, as envisaged in the National Health Policy 2017 along with a separate allocation for the bio-pharmaceutical sector R&D is imperative," Organisation of Pharmaceutical Producers of India (OPPI) President S Sridhar told PTI. The industry saw significant momentum over the past year, especially in ensuring access to COVID-19 vaccines and medicines and this year's Budget will be crucial to accelerate sectoral growth and access to innovative health solutions across various diseases and not COVID ...

Australia's Woolworths makes $613 mln drugstore play, taking on Wesfarmers

The 11th-hour move from Woolworths sets the scene for a bid war between Australia's two largest retail companies

HC seeks Centre, Delhi govt's reply on plea for recruiting medicos

The Delhi High Court sought response of the Centre, the Delhi Government, and others on a plea seeking directions to fill the vacancies of doctors and paramedical staff in government-run hospitals

Health ministry panel vetting requests by six cos to make Mucormycosis drug

Development come amid fast spread of disease in various states and shortage of drugs to treat it; Rajasthan has already declared an epidemic

China halting flights to India could hurt pharma supplies, say companies

China supplies 60% to 70% of the raw materials used by India's drugmakers, according to an expert.

India seeks investments from US companies in pharma, medical devices sector

India has reached out to top American pharma companies seeking investment in the country's pharmaceutical and medical devices sector

India's Covid vaccination drive hangs in balance, and so does the world's

When the pandemic ends, it will be with the tremendous assistance of India's pharmaceutical industry.